March 19, 2026

Wegovy HD Secures FDA Approval

Semaglutide 7.2 mg achieved 20.7% mean weight loss in STEP UP trials.

Conexiant

March 18, 2026

Exercise in a Pill Is Now in Human Trials

Atrogi's ATR-258 just dosed its first subjects — and the muscle data it's hunting could reframe how we treat weight loss.

Conexiant

March 17, 2026

Obesity Medications Get New Guidance

Panel outlines pharmacotherapy roles across obesity complications and long-term weight management.

Conexiant

March 02, 2026

FDA Okays Weekly Option in Achondroplasia

Navepegritide is described as the first therapy to deliver continuous C-type natriuretic peptide exposure over a weekly dosing interval in eligible pediatric patients.

Conexiant

February 12, 2026

FDA Approves HRT Label Changes

The agency cited updated evidence in revising hormone therapy safety language.

Conexiant

January 27, 2026

The Exam Room Is Listening Now

As AI quietly enters exam rooms, physicians report real relief—and real concerns about accuracy, trust, and control.

KFF Health News

January 13, 2026

FDA Drops Warning From GLP-1 RAs

The FDA asked manufacturers to remove suicidal ideation and behavior warnings from select GLP-1 RAs after a comprehensive safety evaluation.

Conexiant

January 13, 2026

FDA Drops Warning From GLP-1 RAs

The FDA asked manufacturers to remove suicidal ideation and behavior warnings from select GLP-1 RAs after a comprehensive safety evaluation.

Conexiant

January 07, 2026

Protein-First Policy Hits US Tables 

New 2025 to 2030 Dietary Guidelines for Americans shift focus to whole foods, full-fat dairy, and protein prioritization while targeting ultraprocessed products as chronic disease drivers

Conexiant

December 04, 2025

FDA Approves Biologic for Nerve Repair

A newly licensed biologic offers a novel approach to repairing complex peripheral nerve injuries across pediatric and adult populations.

Conexiant